Hidden harms

Medication-Related Sexual Dysfunction and Social Disconnection After Injury

A frequently unasked harm can affect identity, relationships, mood and quality of life long after the first prescription.

Why this harm is often missing from the file

Sexual adverse effects are under-discussed. People may feel embarrassed, clinicians may focus on pain or mood, and claim forms rarely ask the right question. The absence of a complaint in early notes does not prove absence of symptoms—but it does make a careful chronology and corroboration important.

Effects can include reduced libido, arousal difficulties, erectile or lubrication problems, delayed or absent orgasm, genital numbness and painful sex. Consequences may extend to self-esteem, intimacy, partnership stability and social participation.

Medicines that may contribute

SSRIs and SNRIs are well recognised causes of sexual dysfunction, and Australian product information now carries aligned warnings that symptoms can persist after cessation in some patients. Opioids can affect endocrine function and contribute to reduced libido and erectile dysfunction. Antipsychotics, some antihypertensives, hormonal therapies and other medicines may also be relevant.

The original injury, pain, depression, PTSD, sleep loss, relationship stress and other disease can produce similar symptoms. Good assessment resists single-cause thinking.

How causation is assessed respectfully

The review should use neutral language and only collect information necessary to answer the referral. Relevant questions include baseline function, symptom onset, medication changes, dose-response, hormonal investigations, other conditions and what occurred during any supervised change in treatment.

Partner evidence may be relevant in some matters, but consent and privacy boundaries matter. A pharmacist opinion can explain medication plausibility and the record; it should not stray into relationship counselling or psychiatric diagnosis.

From hidden symptom to measurable impact

The impact is not limited to intercourse. Avoidance, reduced affection, shame, irritability and fear of rejection can affect the person’s wider recovery. Documenting that pathway can give decision-makers a more complete picture of medication harm without sensationalising it.

Treatment should never be stopped abruptly because of an online article or claim concern. Any change requires the prescriber, particularly where withdrawal or relapse is possible.

References

Primary and authoritative sources

  1. 1Australian Prescriber: persistent sexual dysfunction warnings for antidepressants
  2. 2Australian Prescriber: drug-induced sexual dysfunction
  3. 3Australian Prescriber: opioid-related endocrine and sexual harms

Source links were checked on 25 September 2026. Laws, clinical guidance and individual evidence can change.

Important: This article provides general information only. It is not medical or legal advice and should not be used to start, stop or change treatment or to decide whether it is lawful or safe to drive.

Frequently asked questions

Australian product information now warns that sexual dysfunction may persist after cessation in some patients. It is thought to be rare, and prevalence is not known.
Yes. Pain, depression, PTSD, neurological injury, endocrine disease and relationship factors may all contribute and should be assessed alongside medication exposure.

A question worth testing?

Turn the medication history into a clear evidence pathway.

Start with a privacy-safe summary. We will confirm whether the matter is suitable, what records are needed and the scope of any opinion.